Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences Group (SLS) Liabilities and Shareholders Equity: 2011-2023

Historic Liabilities and Shareholders Equity for SELLAS Life Sciences Group (SLS) over the last 7 years, with Dec 2023 value amounting to $6.2 million.

  • SELLAS Life Sciences Group's Liabilities and Shareholders Equity rose 227.79% to $26.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $72.3 million, marking a year-over-year decrease of 5.77%. This contributed to the annual value of $6.2 million for FY2023, which is 70.31% down from last year.
  • SELLAS Life Sciences Group's Liabilities and Shareholders Equity amounted to $6.2 million in FY2023, which was down 70.31% from $20.9 million recorded in FY2022.
  • In the past 5 years, SELLAS Life Sciences Group's Liabilities and Shareholders Equity registered a high of $46.0 million during FY2020, and its lowest value of $6.2 million during FY2023.
  • For the 3-year period, SELLAS Life Sciences Group's Liabilities and Shareholders Equity averaged around $17.8 million, with its median value being $20.9 million (2022).
  • As far as peak fluctuations go, SELLAS Life Sciences Group's Liabilities and Shareholders Equity surged by 177.25% in 2020, and later slumped by 70.31% in 2023.
  • Over the past 5 years, SELLAS Life Sciences Group's Liabilities and Shareholders Equity (Yearly) stood at $16.6 million in 2019, then spiked by 177.25% to $46.0 million in 2020, then slumped by 42.94% to $26.3 million in 2021, then fell by 20.29% to $20.9 million in 2022, then tumbled by 70.31% to $6.2 million in 2023.